Inhibitory KIR ligands are associated with higher *P. falciparum* parasite prevalence

Jean C. Digitale*[1,2], Perri C. Callaway*[1,3], Maureen Martin[4], George Nelson[5], Mathias Viard[4], John Rek[6], Emmanuel Arinaitwe[6,7], Grant Dorsey[1], Moses Kamya[6,8], Mary Carrington[4,9], Isabel Rodriguez-Barraquer[†1], Margaret E. Feeney[†1,10]

*,[†]These authors contributed equally

[1]Department of Medicine, University of California San Francisco, San Francisco, CA, USA

[2]Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA

[3]Infectious Disease and Immunity Graduate Group, University of California Berkeley, Berkeley, CA, USA

[4]Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA

[5]Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD,

[6]Infectious Diseases Research Collaboration, Kampala, Uganda

[7] London School of Hygiene and Tropical Medicine, London, United Kingdom

[8]Department of Medicine, Makerere University, Kampala, Uganda

[9]Ragon Institute of MGH MIT and Harvard, Cambridge, MA, USA

[10]Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA

Correspondence: Margaret Feeney, 1001 Potrero Avenue, Building 3, Room 545a, San Francisco CA 94110, phone: (628) 206-8218, email: Margaret.feeney@ucsf.edu

The authors have declared that no conflict of interest exists.

Abstract

Killer cell immunoglobulin-like receptors (KIR) and their HLA ligands influence the outcome of many infectious diseases. We analyzed the relationship of compound KIR-HLA genotypes with risk of *Plasmodium falciparum* infection in a longitudinal cohort of 890 Ugandan individuals. We found that presence of HLA-C2 and HLA-Bw4, ligands for inhibitory KIR2DL1 and KIR3DL1, respectively, increased the likelihood of *P. falciparum* parasitemia in an additive manner. Individuals homozygous for HLA-C2, which mediates strong inhibition via KIR2DL1, had the highest odds of parasitemia, HLA-C1/C2 heterozygotes had intermediate odds, and individuals homozygous for HLA-C1, which mediates weaker inhibition through KIR2DL2/3, had the lowest odds of parasitemia. Additionally, higher surface expression of HLA-C, the ligand for inhibitory KIR2DL1/2/3, was associated with a higher likelihood of parasitemia. Together these data indicate that stronger KIR-mediated inhibition confers a higher risk of *P. falciparum* parasitemia and suggest that KIR-expressing effector cells play a role in mediating anti-parasite immunity.

39 **Introduction**

40 *Plasmodium falciparum* malaria has caused hundreds of millions of deaths throughout history
41 and continues to kill nearly half of a million people each year (World Health Organization,
42 2018). As a result, *P. falciparum* has exerted strong selective pressure on human evolution
43 (Kariuki and Williams, 2020; Kwiatkowski, 2005). Most of the human genetic mutations that are
44 known to alter malaria susceptibility lead to erythrocyte defects or cytoadhesion variants
45 (Kariuki and Williams, 2020; Kwiatkowski, 2005). However, a recent GWAS analysis of 17,000
46 individuals estimated that known variants account for only 11% of the total host genetic
47 influence on malaria susceptibility (Band et al., 2019). Surprisingly, only a few gene variants
48 implicated in the host immune response have been robustly associated with malaria
49 susceptibility. Such associations could be particularly valuable in illuminating causal
50 mechanisms of immune protection. Notably, most studies of host genetic susceptibility to
51 malaria, including the GWAS study noted above, have compared severe malaria cases to controls
52 with non-severe (but symptomatic) malaria (Hirayasu et al., 2012; Lourembam et al., 2011). This
53 analytic framework could overlook genes that influence protection at the earlier pre-erythrocytic
54 stages of the *P. falciparum* life cycle, before blood stage infection is established.
55

56 Human killer cell immunoglobulin-like receptors (KIR) are a family of diverse inhibitory and
57 activating transmembrane receptors whose known ligands are primarily HLA class I molecules.
58 The KIR locus is the second most polymorphic region in the human genome after HLA, and is
59 evolving even more rapidly, likely in part due to selective pressure from pathogens (Kulkarni et
60 al., 2008). Human haplotypes vary both in the number of KIR genes and in the proportion that
61 are inhibitory or activating. While some KIR genes are universal, others are expressed by only a

62 subset of individuals (Middleton and Gonzelez, 2010). Moreover, within an individual, only a
63 fraction of cells express a given KIR molecule (Andersson et al., 2009). KIR are expressed on
64 natural killer (NK) cells, some gamma delta T cells, and some CD8 T cells, all of which play a
65 role in the antimalarial immune response (Burrack et al., 2019; Dantzler and Jagannathan, 2018;
66 Lefebvre and Harty, 2019). Interactions of KIR with their HLA ligands modulate the activation
67 threshold of the cell and have been shown to influence the outcome of several, predominantly
68 viral, infections (Bona et al., 2017; Khakoo et al., 2004; Mori et al., 2019). Because the KIR and
69 HLA loci are on different chromosomes and segregate independently, associations of the KIR-
70 HLA compound genotype with susceptibility to a particular pathogen can shed light on
71 mechanisms critical for immunity and immunopathogenesis.
72
73 To date, the association of KIR and their HLA ligands with susceptibility to malaria has been
74 examined in very few studies and almost entirely in the context of case-control comparisons of
75 severe vs. non-severe malaria (Hirayasu et al., 2012; Lourembam et al., 2011). Here, we
76 examined the influence of well-defined KIR-HLA ligand pairs on the prevalence of *P.*
77 *falciparum* parasitemia and malaria in a longitudinal cohort of 890 individuals from three sites
78 with varying malaria transmission in Uganda to determine the influence of KIR on susceptibility
79 to *P. falciparum* infection. This analysis revealed that individuals with more inhibitory KIR-
80 HLA pairs have higher odds of parasitemia, strongly supporting a role for cellular immunity in
81 host restriction of the parasite.

82 **Results**

83 *Clinical cohort and KIR-HLA genotyping*

84 We analyzed data from 657 children and 233 adults recruited from 292 households at three study
85 sites in Uganda (Table 1). Genotyping of KIR and HLA class I loci was performed (Table 2),
86 and individuals were categorized based on the presence of well-characterized KIR ligand groups
87 (i.e. HLA-C2 for KIR2DL1, HLA-C1 for KIR2DL2/3, and HLA-Bw4 for KIR3DL1,
88 Supplemental Table 1). The prevalence of the inhibitory KIR genes KIR2DL1 and KIR3DL1
89 was very high (both >98.5%), consistent with previous reports in East African populations
90 (Nakimuli et al., 2013). In order to control for KIR-HLA differences in ethnicity, participants'
91 ethnicity was categorized as Bantu or non-Bantu based on the language of their consent form
92 (Table 1). However, as ethnicity was largely collinear with site, including it in models did not
93 improve model fit beyond site fixed effects; it was therefore omitted from final analyses.
94
95 Subjects were followed longitudinally from August 2011-June 2016 with blood smears
96 performed every 3 months to assess *P. falciparum* parasitemia. Reflecting the varying
97 transmission intensity among the sites, the prevalence of parasitemia was highest among children
98 in Tororo (64%), followed by Kanungu (36%) and Jinja (13%). The incidence of malaria,
99 defined as parasitemia accompanied by fever (presented at clinic with temperature >38.0℃ or
100 self-reported in last 24 hours), also differed among the three sites and was inversely associated
101 with age (Rodriguez-Barraquer et al., 2018). Both malaria incidence and parasite prevalence by
102 microscopy were substantially lower among adults than children (Table 1).
103
104 To assess whether KIR and their HLA class I ligands influence the risk of *P. falciparum*

105 infection or its clinical manifestations, we tested associations of individual KIR genes, HLA
106 ligand groups and KIR-HLA compound genotypes with 5 malaria outcome measures: prevalence
107 of parasitemia, clinical malaria incidence, parasite density (stratified by routine quarterly visits
108 and malaria visits), conditional probability of clinical malaria given the presence of parasitemia,
109 and temperature at parasitemic visits, conditional on parasite density. For each association, we
110 report the p-value from a multi-level model (p), an empirical p-value after permutation tests (p*),
111 and a q-value (q) calculated by applying the false discovery rate correction for multiple
112 comparisons to the empirical p-values as described in Methods. There was no association
113 between the presence of any individual KIR gene with any of these outcomes (Supplemental
114 Tables 2a-f), so we next assessed the presence of KIRs in conjunction with their HLA ligands.
115
116 *Inhibitory KIR2DL1 ligand HLA-C2 increases risk of* P. falciparum *parasitemia*
117 Among the best characterized KIR-HLA ligand interactions are the inhibitory KIR2DL1 with the
118 HLA-C2 subgroup of HLA-C alleles and KIR2DL2/L3 with the HLA-C1 subgroup. HLA-C2
119 alleles possess a lysine at amino acid position 80 whereas HLA-C1 alleles have an asparagine
120 (Biassoni et al., 1995). Since KIR2DL1 (98.6%) and KIR2DL2/3 (99.3%) were both present in
121 virtually all subjects, the presence of their HLA ligands determines which inhibitory KIR/HLA-
122 C pair(s) an individual has. Further, within these inhibitory KIR/HLA-C ligand interactions,
123 there is a hierarchy of inhibition. KIR2DL1/HLA-C2 provides the strongest inhibition, followed
124 by KIR2DL2/HLA-C1, while KIR2DL3/HLA-C1 provides the weakest inhibition (Carrington et
125 al., 2005; Moesta et al., 2008; Winter et al., 1998). We found that individuals with at least one
126 copy of the KIR2DL1 ligand HLA-C2 had 1.31-fold higher odds of being parasitemic (p=0.017,
127 p*=0.010, q=0.047). Conversely, having at least one HLA-C1 allele decreased the odds of being

128 parasitemic (OR=0.79, p=0.016, p*=0.013, q=0.051).

129

130 Next, we assessed the zygosity of HLA-C ligand groups to determine whether the number of
131 copies of either HLA-C1 or HLA-C2 influenced parasite prevalence. HLA-C1/C1 individuals are
132 only able to receive inhibitory signals via KIR2DL2/3, whereas HLA-C2/C2 individuals receive
133 inhibitory signals predominantly via KIR2DL1, and heterozygous individuals have the ligand for
134 all three of these KIRs (Biassoni et al., 1995). Comparison of these groups revealed a stepwise
135 increase in parasite prevalence, with HLA-C2/C2 individuals having 1.54-fold higher odds of
136 parasitemia compared to HLA-C1/C1 individuals (Table 3). Heterozygous (HLA-C1/C2)
137 individuals had intermediate odds. These results suggest that engagement of KIR2DL1 with its
138 ligand HLA-C2, the most inhibitory of the KIR/HLA-C ligand pairs, increases parasite
139 prevalence in comparison to engagement of KIR2DL2/3 with their ligand HLA-C1, which in
140 general provide weaker inhibitory signals. KIR2DL1 expressing cells from HLA-C2/C2
141 homozygous individuals will receive stronger inhibitory signals, potentially dampening the
142 effector cell response to *P. falciparum* infection.

143

144 KIR2DL2 and KIR2DL3 segregate as alleles of the same locus, but KIR2DL2 provides stronger
145 effector cell inhibition when bound to HLA-C1 (Moesta et al., 2008). Overall, no difference in
146 parasitemia risk was observed between KIR2DL3/C1 and KIR2DL2/C1 individuals (Table 4).
147 However, KIR2DL2 is in linkage disequilibrium with the homologous activating receptor
148 KIR2DS2 (Wn*=0.85, Fisher's exact test p<0.001), which may be capable of binding HLA-C1
149 ligands in a peptide dependent manner (Moesta and Parham, 2012; Naiyer et al., 2017). To test
150 whether KIR2DS2 may have an opposing effect that could obscure the stronger inhibitory impact

151 of KIR2DL2, we examined the impact of KIR2DL2 and KIR2DL3 among individuals lacking
152 the KIR2DS2 gene. This revealed that presence of at least one copy of KIR2DL2 increased the
153 odds of being parasitemic 1.6-fold compared to those with only KIR2DL3 (Table 4). While
154 KIR2DL3/HLA-C1, the least inhibitory KIR-HLA combination in the hierarchy, was associated
155 with a lower prevalence of *P. falciparum* parasitemia, previous data indicate that it markedly
156 increases the risk of cerebral malaria, an inflammatory complication of malaria (Hirayasu et al.,
157 2012). Together these data further support a hierarchy of inhibition, in which KIR-HLA
158 combinations with stronger inhibitory potential increase parasite prevalence.
159
160 *Inhibitory KIR3DL1 ligand HLA-Bw4 increases risk of* P. falciparum *parasitemia*
161 Another inhibitory KIR molecule, KIR3DL1, recognizes a subset of HLA-A and HLA-B alleles
162 that contain the HLA-Bw4 motif, defined by amino acid residues 77-83 on the alpha1-helix
163 (Gumperz et al., 1995). Similar to KIR2DL1, the KIR3DL1 gene was nearly universal in our
164 Ugandan cohort (98.7%), hence its effect on parasite prevalence could not be estimated directly.
165 However, only 74.8% of individuals had an HLA-Bw4 ligand, enabling us to estimate the effect
166 of the KIR-HLA ligand pair. Among individuals with the HLA-Bw4 ligand, the odds of
167 parasitemia were 1.31-fold higher than in individuals lacking HLA-Bw4 ($p=0.012$, $p^*=0.006$,
168 $q=0.040$). This further supports the hypothesis that greater inhibition via KIR increases the
169 likelihood of parasitemia, perhaps due to dampened cellular immunity.
170
171 Because both HLA-C2 and HLA-Bw4 were found to increase parasite prevalence and they have
172 previously been shown to be in linkage disequilibrium, we looked for an additive effect of the
173 two ligand groups by analyzing the combined genotype. Having both HLA-C2 and HLA-Bw4

174 increased the odds of being parasitemic by 1.46 times compared to HLA-C2 alone (p=0.001,
175 p*<0.001, q=0.008) and by 1.51 times compared to HLA-Bw4 alone (p=0.002, p*=0.001,
176 q=0.012), suggesting an additive inhibitory effect of the two KIR-HLA ligand pairs. Together,
177 this supports a model wherein the more inhibitory signals that KIR expressing effector cells can
178 receive, the greater the risk of parasitemia.
179
180 *Higher surface expression of inhibitory KIR ligand HLA-C is associated with increased odds of*
181 *parasitemia*
182 To further elucidate the means by which HLA-C influences *P. falciparum* infection, we
183 examined the relationship of HLA-C surface expression levels to *P. falciparum* parasite
184 prevalence. HLA-C molecules have been ascribed two distinct roles in cellular immunity – as
185 ligands for inhibitory KIR, and as antigen presenting molecules for CD8 T cells – both of which
186 can influence infectious disease outcomes (Bona et al., 2017; Khakoo et al., 2004; Marco et al.,
187 2017). In contrast to HLA-A and -B molecules, surface expression of HLA-C is 10-15 fold lower
188 and varies substantially amongst individual allotypes (Apps et al., 2015). During viral infections
189 such as HIV infection, HLA-C alleles that are more highly expressed at the cell surface have
190 been associated with a more potent CD8 T cell response that correlates with enhanced viral
191 control (Corrah et al., 2011; Thomas et al., 2009). We hypothesized that if the protection
192 associated with certain HLA-C ligand groups is attributable to differences in peptide
193 presentation, then higher HLA-C expression would similarly correlate with a reduced likelihood
194 of parasitemia. We assigned each HLA-C allele a value based on its previously determined
195 expression levels (Apps et al., 2013), and calculated a total HLA-C expression level for each
196 individual. We found that higher HLA-C expression was associated with a statistically

197 significant *increase* in the odds of *P. falciparum* parasitemia (1.12-fold increase per one standard
198 deviation of expression; p=0.014, p*=0.006, q=0.040). This contrasts with HIV infection, where
199 highly expressed HLA-C allotypes are protective against HIV. These data suggest that the
200 mechanism by which HLA-C molecules influence restriction of *P. falciparum* parasitemia is not
201 antigen presentation to T cells, but is more consistent with a role in KIR-mediated inhibition of
202 effector cells.
203
204 *Relationship of KIR-HLA genotype to other parasitological and clinical malaria outcomes*
205 Finally, because the immune mechanisms responsible for restricting parasitemia may differ from
206 those that protect against symptomatic malaria, we also examined the association of KIR-HLA
207 ligand pairs with the other parasitological and clinical outcomes noted above (Supplemental
208 Table 2b-f). We did not observe an association of KIR-HLA ligand pairings with any of these
209 outcomes. Together these results are most consistent with an influence of KIR-expressing
210 effector cells on restriction of parasite replication, rather than on the downstream inflammatory
211 consequences that eventuate in fever and other clinical symptoms.
212
213 In addition, we performed multiple sensitivity analyses to assess the robustness of our results. A
214 more sensitive measure of parasitemia (loop-mediated isothermal amplification—LAMP) was
215 performed on samples that were negative by microscopy at routine visits. However, these data
216 were not included in the primary analyses because LAMP was not conducted consistently on
217 samples from adults at the three sites throughout the study duration. When the definition of
218 parasitemia was expanded to also include the submicroscopic *P. falciparum* infections detectable
219 by LAMP among children for the entire follow-up period (Supplemental Table 3) and among

220 children and adults for the period LAMP data were available for both (Supplemental Table 4),
221 similar associations for all results stated above were observed. In addition, we analyzed models:
222 1) stratified by site (Supplemental Table 5a-c) to determine whether our results were robust
223 across transmission intensities and ethnicities, 2) restricted to children as they suffer the largest
224 burden of parasitemia (Supplemental Table 6), and 3) excluding individuals with hemoglobin S
225 (sickle cell) mutations to ensure our results were not confounded by sickle cell variants
226 (Supplemental Table 7). These secondary analyses yielded similar results, further strengthening
227 our findings.
228
229

230 **Discussion**

231 Using longitudinal data from Ugandan individuals with varying malaria exposure, we found that
232 the major inhibitory KIR ligands HLA-C2 and HLA-Bw4 were both associated with a higher
233 prevalence of *P. falciparum* parasitemia. Our data indicate that both the number of inhibitory
234 KIR-HLA ligand pairs and the strength of their cellular inhibitory signaling influence the risk of
235 *P. falciparum* parasitemia, but notably, do not impact clinical malaria. Our findings suggest that
236 the cellular immune response plays a critical role either in the prevention or clearance of blood-
237 stage *P. falciparum* infection. These associations represent a novel genetic determinant of *P.*
238 *falciparum* parasitemia, and support an expanded role for KIR in modulating host immunity to
239 parasitic infections.

240

241 This novel association of KIR-HLA compound genotypes with the prevalence of parasitemia is
242 somewhat paradoxical given that *P. falciparum* spends most of its life cycle outside of HLA-
243 expressing cells. Following intradermal inoculation by mosquitoes, *P. falciparum* sporozoites
244 migrate via the dermis and lymphatics to infect hepatocytes, the only stage in the parasite
245 replicative life cycle in which it is within an HLA-expressing host cell (Mota et al., 2001).
246 Within the hepatocyte, parasites expand 2,000-40,000 fold, then emerge synchronously as
247 merozoites, which establish a self-propagating cycle of erythrocytic infection (Crutcher and
248 Hoffman, 1996; Sturm et al., 2006). Because erythrocyte membranes contain little to no HLA
249 (Moras et al., 2017), we hypothesize that the influence of KIR on cell-mediated anti-parasite
250 immunity may occur primarily during the liver stage when the multiplicity of infection is also
251 lowest. It has previously been shown that increasing KIR mediated NK cell inhibition is
252 associated with poorer clearance of HCV and HBV in the liver (Bona et al., 2017; Khakoo et al.,

253 2004). However, it is also possible that the observed impacts of KIR-HLA pairs on parasite
254 prevalence may be due to enhanced spontaneous clearance of parasitemia rather than cessation of
255 infection at the liver stage. During the blood stage, KIR-expressing effector cells may respond
256 more strongly to an HLA-devoid cell due to the loss of tonic inhibitory signaling via inhibitory
257 KIR (Kim et al., 2008). KIR inhibition may also influence the clearance of parasites through
258 antibody dependent cellular cytotoxicity (ADCC) (Lisovsky et al., 2019; Parsons et al., 2010).
259
260 It is notable that we did not observe an influence of KIR or their HLA ligands on symptomatic
261 malaria. In endemic regions, "clinical immunity"—defined as protection from symptomatic
262 malaria–develops gradually with increasing age and exposure to the *P. falciparum* parasite, but
263 sterilizing immunity (i.e. protection against parasitemia) does not (Tran et al., 2013). Hence, it is
264 likely that the immune mechanisms underlying sterile protection and restriction of parasite
265 replication differ from those that mediate clinical immunity, with the latter involving
266 immunoregulatory processes that dampen the inflammation responsible for fever and other
267 symptoms, while fostering successful long-term parasitism. By definition, sterile immunity is
268 directed at the pre-erythrocytic (sporozoite and liver) stages of parasite development. The pre-
269 erythrocytic immune response can prevent or greatly limit the establishment of blood-stage
270 parasitemia and is believed to be mediated by CD8 T cells (Hafalla et al., 2006; Lefebvre and
271 Harty, 2019), NK cells (Arora et al., 2018; Hart et al., 2019, 2017) and the semi-innate Vγ9Vδ2
272 subset of γδ T cells (Farrington et al., 2016; Jagannathan et al., 2014; Mamedov et al., 2018;
273 Zaidi et al., 2017), all of which can express KIR. It remains possible that KIR-HLA interactions
274 exert an impact on the symptomatic or inflammatory manifestations of malaria that we were
275 underpowered to detect, given that all members of this study cohort had access to free clinical

276 care which afforded prompt diagnosis and treatment of malaria. Indeed, Hirayasu et. al. reported
277 that the risk of cerebral malaria, an inflammatory complication, is markedly elevated among
278 individuals with KIR2DL3/HLA-C1, which is the least inhibitory pairing amongst KIR2DL1/2/3
279 ligands (Hirayasu et al., 2012). Immunopathology contributes substantially to the neurological
280 damage caused by cerebral malaria (Grau et al., 1989) and NK cells have been found to
281 accumulate in the brain microvasculature (Hansen et al., 2007). Thus, lower KIR inhibition could
282 allow unrestrained NK cell activation resulting in immune-mediated pathology in the brain. This
283 would be consistent with the hypothesis that mechanisms that prevent initial *P. falciparum*
284 infection and those that prevent severe disease are distinct and may have a balancing effect on
285 the maintenance of different KIR and HLA ligands in malaria endemic populations.
286
287 The results of our study also underscore that case-control studies of severe vs. non-severe
288 malaria have important limitations as a framework to identify immune susceptibility genes.
289 Because such comparisons are restricted to individuals in whom parasitemia is already
290 established, they cannot identify genetic factors influencing host restriction at the pre-
291 erythrocytic stages of infection. Moreover, the development of severe malaria is likely to be
292 influenced by genetic factors governing inflammation, as well as non-genetic factors such as
293 socio-economic status and access to care. We believe that additional genetic determinants of
294 malaria may be uncovered through analytic methods that incorporate rigorous longitudinal
295 assessments of both parasite infection and symptoms, enabling evaluation of immune protection
296 at varying stages of malaria: from initial infection and establishment of parasitemia, to
297 development of symptomatic or even severe malaria.
298

299 While it is well established that KIRs influence the immune response to and ultimate outcome of
300 numerous viral infections, their impact on the control of non-viral infections has been less
301 certain. Our finding that inhibitory KIR ligands increase the risk of *P. falciparum* parasitemia
302 indicates that the influence of KIR on host immunity extends to parasitic infections. Moreover,
303 our findings suggest an important role for the cellular immune response in restricting *P.*
304 *falciparum* infection, perhaps during the earliest stages of infection, before blood-stage
305 parasitemia is established. These findings represent a novel genetic determinant of malaria
306 susceptibility and further our understanding of antimalarial immunity with implications for
307 vaccine design.
308

309

310 **Methods**

311 *Study Approval*

312 This study was granted ethical approval from the Makerere University School of Medicine
313 Research and Ethics Committee, the London School of Hygiene and Tropical Medicine Ethics
314 Committee, the University of California, San Francisco, Committee on Human Research and the
315 Uganda National Council for Science and Technology. All participants and/or their
316 parents/guardians gave written informed consent for their household upon enrollment.

317 *Clinical and parasitological outcomes*

318 Data were collected from Ugandan subjects enrolled into three parallel longitudinal cohorts
319 conducted as part of the East Africa International Center of Excellence for Malaria Research, at
320 sites with a range of malaria transmission intensity. Nagongera, in Tororo district, is a high-
321 transmission, rural area in southeastern Uganda. Kihihi, in Kanungu district, is a rural area in
322 southwestern Uganda with moderate transmission. Walukuba, in Jinja district, is a relatively low-
323 transmission, peri-urban area near Lake Victoria. Households in the three sites were enumerated
324 and approximately 100 households per site were randomly selected. All children aged 6 months
325 to 10 years and one adult caregiver per household who met eligibility criteria (usually a female)
326 were invited to participate between August and October 2011. Children aged out of the cohort
327 when they reached 11 years of age. Participants were followed through June 2016; visits after
328 December 31, 2014 from Tororo were excluded from this analysis because transmission changed
329 dramatically at this site after intensive indoor residual spraying campaigns were started. Analytic
330 follow-up time was a median of 55 months in Jinja, 57 months in Kanungu, and 39 months in
331 Tororo. Further detail on the cohort is available from Kamya et al. (Kamya et al., 2015).

332

333 Clinical data were obtained via both active and passive follow-up. All participants visited the
334 clinic quarterly to obtain thick blood smears. In addition, caregivers were asked to bring their
335 children to study clinics to receive care for any illness free of charge. Thick blood smears were
336 performed on all children who reported fever in the previous 24 hours or who were febrile
337 (>38.0°C) at the sick visit. Parasitemia was determined based on microscopy and parasite density
338 was calculated as previously described (Rodriguez-Barraquer et al., 2018). A more sensitive
339 measure of parasitemia (loop-mediated isothermal amplification—LAMP) was performed on
340 samples negative by microscopy at routine visits throughout follow-up for children. However,
341 LAMP was not conducted consistently on samples from adults at all sites throughout the study
342 duration and thus was not included in primary analyses. Those with symptomatic malaria were
343 treated with the first line treatment in Uganda, artemether-lumefantrine. Those with complicated
344 or recurrent malaria (occurring within 14 days of last therapy) were treated with quinine
345 (Rodriguez-Barraquer et al., 2018).
346
347 Entomologic data were collected monthly at all study households. Mosquitoes were collected
348 using miniature CDC light traps and tested for sporozoites using an ELISA technique, as
349 previously described (Kilama et al., 2014). For each household an annual entomological
350 inoculation rate (EIR) was calculated as the product of the of the yearly household human biting
351 rate (geometric mean of female Anopheles mosquitoes caught in a household per day) and the
352 site sporozoite rate (average proportion of mosquitos that tested positive for *P. falciparum* in
353 each site), as previously reported (Rodriguez-Barraquer et al., 2018).
354
355 *HLA and KIR Genotyping*

356 HLA genotyping was performed using a targeted next generation sequencing (NGS) method.
357 Briefly, locus-specific primers were used to amplify a total of 23 polymorphic exons of HLA-A,
358 B, C (exons 1 to 4), DPA1 (exon 2), DPB1 (exons 2, 3), DQA1 (exon 2), DQB1 (exons 2, 3),
359 DRB1 (exons 2, 3), and DRB3, 4, 5 (exon 2) genes with Fluidigm Access Array (Fluidigm
360 Singapore PTE Ltd, Singapore). The 23 Fluidigm PCR amplicons were pooled and subjected to
361 sequencing on an illumina MiSeq sequencer (Illumina, San Diego, CA). HLA alleles and
362 genotypes were called using the Omixon HLA Explore (beta version) software (Omixon,
363 Budapest, Hungary).
364
365 KIR genotyping for the presence or absence of each KIR gene was conducted by PCR with
366 sequence-specific priming (PCR-SSP) as described previously (Martin and Carrington, 2008),
367 with some modifications. Each PCR was conducted in a volume of 5 ul using 5 ng genomic
368 DNA and SYBR Green PCR Master Mix with Platinum Taq (Invitrogen). Presence and absence
369 of specific PCR products was detected by melting curve analysis on the 7900 Real-Time PCR
370 System (Applied Biosystems).
371
372 *HLA-C Expression Levels*
373 HLA-C expression levels were imputed using estimates based on previously published
374 quantitative measurements of HLA-C allotypes (Apps et al., 2013).
375
376 *Statistics*
377 We analyzed the association of KIR and their HLA ligands with five different outcomes related
378 to malaria immunity:

379 1. Parasite prevalence: Prevalence of at least one symptomatic or asymptomatic parasite
380 positive visit per quarter (by microscopy).
381 2. Annual malaria incidence rate: Number of symptomatic malaria episodes per person-
382 year. Symptomatic malaria was defined as children with a tympanic temperature >38°C
383 at time of presentation to clinic plus parasitemia or those with a self-reported history of
384 fever in past 24 hours plus parasitemia.
385 3. Parasite density: Log parasite density measured during visit (in analyses, stratified by two
386 visit types: routine quarterly parasite-positive visits and symptomatic malaria visits).
387 4. Probability of symptoms if infected: Whether a participant was febrile if they were
388 parasitemic. (Episodes of asymptomatic parasitemia where fever developed within 7 days
389 and repeat episodes of febrile parasitemia within 7 days of initial episode were excluded
390 so that each malarial episode was only counted once.)
391 5. Temperature at parasitemic visits: Objective temperature at parasitemic visits, conditional
392 on parasite density.
393
394 First, we assessed the effect of each KIR individually on these outcomes. Next, we explored
395 KIR-HLA compound genotypes as follows. HLA ligand group definitions are in Supplemental
396 Table 1. KIR2DL1, which binds HLA-C2, was present in nearly all subjects (98.6%). KIR2DL2
397 and KIR2DL3 segregate as alleles of the same locus and have the same HLA ligand, HLA-C1;
398 virtually everyone in this sample has KIR2DL2 and/or KIR2DL3 (99.3%). We examined the
399 effect of having at least one copy of HLA-C2 among those with KIR2DL1 and of having at least
400 one copy of HLA-C1 among those with KIR2DL2 and/or KIR2DL3. Building on this, we
401 investigated HLA-C1/C2 zygosity in the entire sample to determine the effect of multiple copies

402 of each ligand. We then assessed the effect of a joint variable: no HLA-C1 ligand (i.e. HLA-C2
403 homozygous), HLA-C1 with KIR2DL2 only, HLA-C1 with KIR2DL2 and KIR2DL3, or HLA-
404 C1 with KIR2DL3 only. We repeated this analysis among those with no KIR2DS2 (for the
405 outcome of parasite prevalence only). Another inhibitory KIR, KIR3DL1, was also nearly
406 ubiquitous in the sample (98.7%). We again considered the effect of its ligand, HLA-Bw4,
407 among those with the receptor. Given that both HLA-C2 and Bw4 affected parasite prevalence in
408 the same direction, we assessed the combined genotype of HLA-C2 and HLA-Bw4 (neither
409 HLA-C2 nor HLA-Bw4, only HLA-C2, only HLA-Bw4, or both HLA-C2 and HLA-Bw4).
410 Finally, we looked at the level of HLA-C expression (normalized as a z-score).
411
412 To estimate these effects, we used multi-level models with random effects at the individual- and
413 household-levels. We used logistic regression for parasite prevalence and probability of
414 symptoms if infected. We used Poisson models for malaria incidence. We used linear models for
415 log parasite density, as well as temperature. All models were adjusted for site, household log
416 entomological inoculation rate, and sex. Models included a continuous linear term for age, a
417 binary indicator of age group (child vs. adult), and an interaction between the two to allow for
418 effects to vary between age groups, because the study did not enroll participants between the
419 ages of 11 and 17. Models for temperature also controlled for log parasite density at that visit.
420
421 In summary, the models followed this general form (an example model for parasite prevalence
422 shown):
423

$$logit(Parasite\ prevalence_{ijk}) = KIR\text{-}HLA\ compound\ genotype_{ij} + Site_i + Log(aEIR_i) + Sex_{ij} + Age_{ijk} + Child_{ij} + Age*Child_{ijk} + u_i + y_j$$

where i indicates households, j indicates individuals, and k indicates specific visits. For example, age_{ijk} denotes the age of child j from household i during visit k. As $aEIR_i$ represents the average annual EIR recorded for household i (time-invariant), we assume relatively stable transmission intensity over the course of study follow-up.

We used Monte Carlo permutation tests to calculate exact p-values. We permuted exposure variables 10,000 times and calculated the two-sided p-value as the number of permutations that yielded coefficients greater than or equal to the absolute value of the observed coefficient divided by the number of models that converged (>99%) using the Stata ritest package version 1.1.4 (Heß, 2017). For each outcome, we controlled for multiple testing separately using the false discovery rate (FDR) approach with the Stata qqvalue package (Newson, 2010). All analysis was done in Stata 15.1 (StataCorp, College Station, TX).

Finally, we performed the following sensitivity analyses for all models with the outcome of parasite prevalence: stratified by site, among children only, and among sickle cell wild type. We also estimated models using a measure of parasitemia defined as positive if a subject were positive either by microscopy or by LAMP among children for the entire follow-up period and among children and adults for the period LAMP data were available for both. Controlling for ethnicity (Bantu/non-Bantu) based on the language of their consent form did not improve model fit as compared to controlling for site because these two variables were collinear.

447 **Author Contributions**

448 JCD, PCC, IRB and MEF designed experimental questions. IRB and JCD created statistical
449 analysis plan and JCD performed all statistical analyses. PCC, MEF and JCD prepared original
450 manuscript. GD, MK, EA and JR generated the clinical data set. MM and MC performed KIR
451 and HLA genotyping. GN and MV validated statistical analyses. All authors contributed to
452 review and editing of manuscript.

453

Acknowledgments

We are grateful to all the parents and guardians for kindly giving their consent, and to the study participants for their cooperation. We thank all the members of the study team for their tireless effort and excellent work. We thank Noam Teyssier for generously sharing his computing expertise and time. Support for this work was provided by the National Institute of Allergy and Infectious Diseases (R01AI093615 and K24AI113002 to M.E.F., U19AI089674 to M.E.F., G.D. and M.K) and Henry Wheeler Center for Emerging and Neglected Diseases (to P.C.C.). In addition, this project has been funded in part with federal funds from the Frederick National Laboratory for Cancer Research, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This Research was supported in part by the Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer Research.

470 **Tables and Figures**

471

472 **Table 1. Characteristics of study population**

	Jinja	**Kanungu**	**Tororo**
Households (N)	**97**	**100**	**95**
Median household EIR (range)	2.1 (1.5-22.0)	6.3 (3.0-44.5)	67.6 (11.5-588.4)
Adults (N)	**89**	**78**	**66**
Median incidence of symptomatic malaria episodes per person year (range)	0.0 (0.0-2.0)	0.2 (0.0-3.7)	0.0 (0.0-3.0)
Parasite prevalence (% quarters parasite+)	4.9%	12.8%	12.0%
Children (N)	**187**	**267**	**203**
Median age at enrollment, years (range)	4.4 (0.5-10.0)	4.7 (0.5-9.9)	5.1 (0.6-10.0)
Median incidence of symptomatic malaria episodes per person year (range)	0.2 (0.0-5.1)	1.2 (0.0-8.1)	2.1 (0.0-8.8)
Parasite prevalence (% quarters parasite +, range)	12.8%	36.4%	64.2%
Median follow up time, months (range)*	55.1 (2.3-58.6)	56.7 (0.0-58.3)	39.0 (1.8-40.3)
Sickle cell, n(%)			
AA	201 (72.8%)	323 (93.6%)	195 (72.5%)
AS	72 (26.1%)	22 (6.4%)	70 (26.0%)
SS	0 (0.0%)	0 (0.0%)	2 (0.7%)
No result	3 (1.1%)	0 (0.0%)	2 (0.7%)
Bantu ethnicity, N (%)	180 (65.5%)	341 (98.8%)	2 (0.7%)

*Note: 3 people in the sample had only one visit; Tororo visits after December 31, 2014 were excluded because transmission changed dramatically at this site after intensive indoor residual spraying campaigns were started.

473

474

475 **Table 2. KIR and Ligand Prevalence**

KIR and HLA prevalence	**N=890**
KIR	%
KIR2DL1†	98.6
KIR2DL2	54.7
KIR2DL3‡	84.8
KIR2DL4	99.7
KIR2DL5	57.9
KIR2DP1	98.1
KIR2DS1	23.5
KIR2DS2	49.0
KIR2DS3	23.0
KIR2DS4	68.3
KIR2DS5	42.6
KIR3DL1	98.7
KIR3DL2	99.6
KIR3DS1	13.0
HLA	%
C1/C2 ligand group zygosity*	
C1/C1	19.5
C1/C2	53.1
C2/C2	27.4
Bw4 ligand group (at least one copy)	74.8

Note: Reduced Ns due to failed amplification or lack of DNA.

†N=888

‡N=883

*N=889

476

477 **Table 3. Effect of HLA-C zygosity on parasite prevalence**

C1/C2 zygosity	OR	P-value	Empirical p-value	Empirical FDR q-value	N
C1/C1	Ref				173
C1/C2	1.26	0.045	0.036	0.111	472
C2/C2	1.54	0.001	0.001	0.008	244

478

479 **Table 4. Effect of KIR2DL2/3 on parasite prevalence**

	OR	P-value	Empirical p-value	Empirical FDR q-value	N
2DL2/3					
no C1	1.24	0.061	0.045	0.115	244
C1 + 2DL2 only	1.03	0.845	0.837	0.837	87
C1 + 2DL2/2DL3	0.93	0.543	0.510	0.640	273
C1 + 2DL3 only	Ref				278
2DL2/3 among those without 2DS2					
no C1	1.19	0.199	0.171	0.354	136
C1 + 2DL2 only or 2DL2/2DL3	1.60	0.024	0.016	0.056	45
C1 + 2DL3 only	Ref				272

480

481

482 **References**

483 Andersson S, Fauriat C, Malmberg J-A, Ljunggren H-G, Malmberg K-J. 2009. KIR acquisition
484 probabilities are independent of self-HLA class I ligands and increase with cellular KIR
485 expression. *Blood* **114**:95–104. doi:10.1182/blood-2008-10-184549
486 Apps R, Meng Z, Prete GQD, Lifson JD, Zhou M, Carrington M. 2015. Relative Expression
487 Levels of the HLA Class-I Proteins in Normal and HIV-Infected Cells. *The Journal of*
488 *Immunology* **194**:3594–3600. doi:10.4049/jimmunol.1403234
489 Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, Yuki Y, Del Prete GQ, Goulder P,
490 Brumme ZL, Brumme CJ, John M, Mallal S, Nelson G, Bosch R, Heckerman D, Stein
491 JL, Soderberg KA, Moody MA, Denny TN, Zeng X, Fang J, Moffett A, Lifson JD,
492 Goedert JJ, Buchbinder S, Kirk GD, Fellay J, McLaren P, Deeks SG, Pereyra F, Walker
493 B, Michael NL, Weintrob A, Wolinsky S, Liao W, Carrington M. 2013. Influence of
494 HLA-C expression level on HIV control. *Science* **340**:87–91.
495 doi:10.1126/science.1232685
496 Arora G, Hart GT, Manzella-Lapeira J, Doritchamou JY, Narum DL, Thomas LM, Brzostowski
497 J, Rajagopalan S, Doumbo OK, Traore B, Miller LH, Pierce SK, Duffy PE, Crompton
498 PD, Desai SA, Long EO. 2018. NK cells inhibit Plasmodium falciparum growth in red
499 blood cells via antibody-dependent cellular cytotoxicity. *eLife Sciences* **7**:e36806.
500 doi:10.7554/eLife.36806
501 Band G, Le QS, Clarke GM, Kivinen K, Hubbart C, Jeffreys AE, Rowlands K, Leffler EM,
502 Jallow M, Conway DJ, Sisay-Joof F, Sirugo G, d'Alessandro U, Toure OB, Thera MA,
503 Konate S, Sissoko S, Mangano VD, Bougouma EC, Sirima SB, Amenga-Etego LN,
504 Ghansah AK, Hodgson AVO, Wilson MD, Enimil A, Ansong D, Evans J, Ademola SA,
505 Apinjoh TO, Ndila CM, Manjurano A, Drakeley C, Reyburn H, Phu NH, Quyen NTN,
506 Thai CQ, Hien TT, Teo YY, Manning L, Laman M, Michon P, Karunajeewa H, Siba P,
507 Allen S, Allen A, Bahlo M, Davis TME, Simpson V, Shelton J, Spencer CCA, Busby
508 GBJ, Kerasidou A, Drury E, Stalker J, Dilthey A, Mentzer AJ, McVean G, Bojang KA,
509 Doumbo O, Modiano D, Koram KA, Agbenyega T, Amodu OK, Achidi E, Williams TN,
510 Marsh K, Riley EM, Molyneux M, Taylor T, Dunstan SJ, Farrar J, Mueller I, Rockett
511 KA, Kwiatkowski DP, Malaria Genomic Epidemiology Network. 2019. Insights into
512 malaria susceptibility using genome-wide data on 17,000 individuals from Africa, Asia
513 and Oceania. *Nature Communications* **10**:1–19. doi:10.1038/s41467-019-13480-z
514 Biassoni R, Falco M, Cambiaggi A, Costa P, Verdiani S, Pende D, Conte R, Di Donato C,
515 Parham P, Moretta L. 1995. Amino acid substitutions can influence the natural killer
516 (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the
517 target cell protection from lysis mediated by group 2 or group 1 NK clones. *J Exp Med*
518 **182**:605–609. doi:10.1084/jem.182.2.605
519 Bona DD, Aiello A, Colomba C, Bilancia M, Accardi G, Rubino R, Giannitrapani L,
520 Tuttolomondo A, Cascio A, Caiaffa MF, Rizzo S, Lorenzo GD, Candore G, Duro G,
521 Macchia L, Montalto G, Caruso C. 2017. KIR2DL3 and the KIR ligand groups HLA-A-
522 Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection. *Journal of Viral*
523 *Hepatitis* **24**:768–775. doi:10.1111/jvh.12698
524 Burrack KS, Hart GT, Hamilton SE. 2019. Contributions of natural killer cells to the immune
525 response against Plasmodium. *Malaria Journal* **18**:321. doi:10.1186/s12936-019-2953-1

526 Carrington M, Wang S, Martin MP, Gao X, Schiffman M, Cheng J, Herrero R, Rodriguez AC,
527 Kurman R, Mortel R, Schwartz P, Glass A, Hildesheim A. 2005. Hierarchy of resistance
528 to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor
529 and human leukocyte antigen loci. *The Journal of Experimental Medicine* **201**:1069–
530 1075. doi:10.1084/jem.20042158
531 Corrah TW, Goonetilleke N, Kopycinski J, Deeks SG, Cohen MS, Borrow P, McMichael A,
532 Brackenridge S. 2011. Reappraisal of the Relationship between the HIV-1-Protective
533 Single-Nucleotide Polymorphism 35 Kilobases Upstream of the HLA-C Gene and
534 Surface HLA-C Expression. *J Virol* **85**:3367–3374. doi:10.1128/JVI.02276-10
535 Crutcher JM, Hoffman SL. 1996. Malaria In: Baron S, editor. Medical Microbiology. Galveston
536 (TX): University of Texas Medical Branch at Galveston.
537 Dantzler KW, Jagannathan P. 2018. γδ T Cells in Antimalarial Immunity: New Insights Into
538 Their Diverse Functions in Protection and Tolerance. *Front Immunol* **9**.
539 doi:10.3389/fimmu.2018.02445
540 Farrington LA, Jagannathan P, McIntyre TI, Vance HM, Bowen K, Boyle MJ, Nankya F,
541 Wamala S, Auma A, Nalubega M, Sikyomu E, Naluwu K, Bigira V, Kapisi J, Dorsey G,
542 Kamya MR, Feeney ME. 2016. Frequent Malaria Drives Progressive Vδ2 T-Cell Loss,
543 Dysfunction, and CD16 Up-regulation During Early Childhood. *J Infect Dis* **213**:1483–
544 1490. doi:10.1093/infdis/jiv600
545 Grau GE, Heremans H, Piguet PF, Pointaire P, Lambert PH, Billiau A, Vassalli P. 1989.
546 Monoclonal antibody against interferon gamma can prevent experimental cerebral
547 malaria and its associated overproduction of tumor necrosis factor. *PNAS* **86**:5572–5574.
548 doi:10.1073/pnas.86.14.5572
549 Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. 1995. The Bw4 public epitope of
550 HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a
551 putative HLA receptor. *J Exp Med* **181**:1133–1144. doi:10.1084/jem.181.3.1133
552 Hafalla JCR, Cockburn IA, Zavala F. 2006. Protective and pathogenic roles of CD8+ T cells
553 during malaria infection. *Parasite Immunology* **28**:15–24. doi:10.1111/j.1365-
554 3024.2006.00777.x
555 Hansen DS, Bernard NJ, Nie CQ, Schofield L. 2007. NK Cells Stimulate Recruitment of
556 CXCR3+ T Cells to the Brain during Plasmodium berghei-Mediated Cerebral Malaria.
557 *The Journal of Immunology* **178**:5779–5788. doi:10.4049/jimmunol.178.9.5779
558 Hart GT, Theorell J, Tran T, Arora G, Crompton PD, Bryceson Y, Long EO. 2017. Antibody-
559 dependent NK cell control of Plasmodium falciparum infection. *The Journal of*
560 *Immunology* **198**:68.19-68.19.
561 Hart GT, Tran TM, Theorell J, Schlums H, Arora G, Rajagopalan S, Sangala ADJ, Welsh KJ,
562 Traore B, Pierce SK, Crompton PD, Bryceson YT, Long EO. 2019. Adaptive NK cells in
563 people exposed to Plasmodium falciparum correlate with protection from malaria.
564 *Journal of Experimental Medicine* jem.20181681. doi:10.1084/jem.20181681
565 Heß S. 2017. Randomization Inference with Stata: A Guide and Software: *The Stata Journal*.
566 doi:10.1177/1536867X1701700306
567 Hirayasu K, Ohashi J, Kashiwase K, Hananantachai H, Naka I, Ogawa A, Takanashi M, Satake
568 M, Nakajima K, Parham P, Arase H, Tokunaga K, Patarapotikul J, Yabe T. 2012.
569 Significant Association of KIR2DL3-HLA-C1 Combination with Cerebral Malaria and
570 Implications for Co-evolution of KIR and HLA. *PLOS Pathogens* **8**:e1002565.
571 doi:10.1371/journal.ppat.1002565

572 Jagannathan P, Kim CC, Greenhouse B, Nankya F, Bowen K, Eccles-James I, Muhindo MK,
573 Arinaitwe E, Tappero JW, Kamya MR, Dorsey G, Feeney ME. 2014. Loss and
574 dysfunction of Vδ2^{+} γδ T cells are associated with clinical tolerance to malaria. *Sci*
575 *Transl Med* **6**:251ra117. doi:10.1126/scitranslmed.3009793
576 Kamya MR, Arinaitwe E, Wanzira H, Katureebe A, Barusya C, Kigozi SP, Kilama M, Tatem
577 AJ, Rosenthal PJ, Drakeley C, Lindsay SW, Staedke SG, Smith DL, Greenhouse B,
578 Dorsey G. 2015. Malaria Transmission, Infection, and Disease at Three Sites with Varied
579 Transmission Intensity in Uganda: Implications for Malaria Control. *Am J Trop Med Hyg*
580 **92**:903–912. doi:10.4269/ajtmh.14-0312
581 Kariuki SN, Williams TN. 2020. Human genetics and malaria resistance. *Hum Genet* **139**:801–
582 811. doi:10.1007/s00439-020-02142-6
583 Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ,
584 Vlahov D, Hilgartner M, Cox S, Little A-M, Alexander GJ, Cramp ME, O'Brien SJ,
585 Rosenberg WMC, Thomas DL, Carrington M. 2004. HLA and NK Cell Inhibitory
586 Receptor Genes in Resolving Hepatitis C Virus Infection. *Science* **305**:872–874.
587 doi:10.1126/science.1097670
588 Kilama M, Smith DL, Hutchinson R, Kigozi R, Yeka A, Lavoy G, Kamya MR, Staedke SG,
589 Donnelly MJ, Drakeley C, Greenhouse B, Dorsey G, Lindsay SW. 2014. Estimating the
590 annual entomological inoculation rate for Plasmodium falciparum transmitted by
591 Anopheles gambiae s.l. using three sampling methods in three sites in Uganda. *Malaria*
592 *Journal* **13**:111. doi:10.1186/1475-2875-13-111
593 Kim S, Sunwoo JB, Yang L, Choi T, Song Y-J, French AR, Vlahiotis A, Piccirillo JF, Cella M,
594 Colonna M, Mohanakumar T, Hsu KC, Dupont B, Yokoyama WM. 2008. HLA alleles
595 determine differences in human natural killer cell responsiveness and potency. *Proc Natl*
596 *Acad Sci U S A* **105**:3053–3058. doi:10.1073/pnas.0712229105
597 Kulkarni S, Martin MP, Carrington M. 2008. The Ying and Yang of HLA and KIR in Human
598 Disease. *Semin Immunol* **20**:343–352. doi:10.1016/j.smim.2008.06.003
599 Kwiatkowski DP. 2005. How Malaria Has Affected the Human Genome and What Human
600 Genetics Can Teach Us about Malaria. *The American Journal of Human Genetics*
601 **77**:171–192. doi:10.1086/432519
602 Lefebvre MN, Harty JT. 2019. You Shall Not Pass: Memory CD8 T Cells in Liver-Stage
603 Malaria. *Trends in Parasitology*. doi:10.1016/j.pt.2019.11.004
604 Lisovsky I, Kant S, Tremblay-McLean A, Isitman G, Kiani Z, Dupuy FP, Gilbert L, Bruneau J,
605 Shoukry NH, Lebouché B, Bernard NF. 2019. Differential contribution of education
606 through KIR2DL1, KIR2DL3, and KIR3DL1 to antibody-dependent (AD) NK cell
607 activation and ADCC. *Journal of Leukocyte Biology* **105**:551–563.
608 doi:10.1002/JLB.4A0617-242RRR
609 Lourembam SD, Sawian CE, Baruah S. 2011. Differential association of KIR gene loci to risk of
610 malaria in ethnic groups of Assam, Northeast India. *Infection, Genetics and Evolution*
611 **11**:1921–1928. doi:10.1016/j.meegid.2011.08.017
612 Mamedov MR, Scholzen A, Nair RV, Cumnock K, Kenkel JA, Oliveira JHM, Trujillo DL,
613 Saligrama N, Zhang Y, Rubelt F, Schneider DS, Chien Y, Sauerwein RW, Davis MM.
614 2018. A Macrophage Colony-Stimulating Factor-Producing γδ T Cell Subset Prevents
615 Malarial Parasitemic Recurrence. *Immunity* **0**. doi:10.1016/j.immuni.2018.01.009
616 Marco MD, Schuster H, Backert L, Ghosh M, Rammensee H-G, Stevanović S. 2017. Unveiling
617 the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and

618 Generation of Binding Prediction Matrices. *The Journal of Immunology* **199**:2639–2651.
619 doi:10.4049/jimmunol.1700938
620 Martin MP, Carrington M. 2008. KIR locus polymorphisms: genotyping and disease association
621 analysis. *Methods Mol Biol* **415**:49–64. doi:10.1007/978-1-59745-570-1_3
622 Middleton D, Gonzelez F. 2010. The extensive polymorphism of KIR genes. *Immunology* **129**:8–
623 19. doi:10.1111/j.1365-2567.2009.03208.x
624 Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. 2008. Synergistic
625 Polymorphism at Two Positions Distal to the Ligand-Binding Site Makes KIR2DL2 a
626 Stronger Receptor for HLA-C Than KIR2DL3. *The Journal of Immunology* **180**:3969–
627 3979. doi:10.4049/jimmunol.180.6.3969
628 Moesta AK, Parham P. 2012. Diverse functionality among human NK cell receptors for the C1
629 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3. *Front Immunol* **3**.
630 doi:10.3389/fimmu.2012.00336
631 Moras M, Lefevre SD, Ostuni MA. 2017. From Erythroblasts to Mature Red Blood Cells:
632 Organelle Clearance in Mammals. *Front Physiol* **8**. doi:10.3389/fphys.2017.01076
633 Mori M, Leitman E, Walker B, Ndung'u T, Carrington M, Goulder P. 2019. Impact of HLA
634 Allele-KIR Pairs on HIV Clinical Outcome in South Africa. *J Infect Dis* **219**:1456–1463.
635 doi:10.1093/infdis/jiy692
636 Mota MM, Pradel G, Vanderberg JP, Hafalla JCR, Frevert U, Nussenzweig RS, Nussenzweig V,
637 Rodríguez A. 2001. Migration of Plasmodium Sporozoites Through Cells Before
638 Infection. *Science* **291**:141–144. doi:10.1126/science.291.5501.141
639 Naiyer MM, Cassidy SA, Magri A, Cowton V, Chen K, Mansour S, Kranidioti H, Mbirbindi B,
640 Rettman P, Harris S, Fanning LJ, Mulder A, Claas FHJ, Davidson AD, Patel AH,
641 Purbhoo MA, Khakoo SI. 2017. KIR2DS2 recognizes conserved peptides derived from
642 viral helicases in the context of HLA-C. *Science Immunology* **2**:eaal5296.
643 doi:10.1126/sciimmunol.aal5296
644 Nakimuli A, Chazara O, Farrell L, Hiby SE, Tukwasibwe S, Knee O, Jayaraman J, Traherne JA,
645 Elliott AM, Kaleebu P, Mirembe F, Moffett A. 2013. Killer cell immunoglobulin-like
646 receptor (KIR) genes and their HLA-C ligands in a Ugandan population. *Immunogenetics*
647 **65**:765–775. doi:10.1007/s00251-013-0724-7
648 Newson RB. 2010. Frequentist Q-values for Multiple-test Procedures. *The Stata Journal* **10**:568–
649 584. doi:10.1177/1536867X1101000403
650 Parsons MS, Zipperlen K, Gallant M, Grant M. 2010. Killer cell immunoglobulin-like receptor
651 3DL1 licenses CD16-mediated effector functions of natural killer cells. *Journal of*
652 *Leukocyte Biology* **88**:905–912. doi:10.1189/jlb.1009687
653 Rodriguez-Barraquer I, Arinaitwe E, Jagannathan P, Kamya MR, Rosenthal PJ, Rek J, Dorsey G,
654 Nankabirwa J, Staedke SG, Kilama M, Drakeley C, Ssewanyana I, Smith DL,
655 Greenhouse B. 2018. Quantification of anti-parasite and anti-disease immunity to malaria
656 as a function of age and exposure. *eLife*. doi:10.7554/eLife.35832
657 Sturm A, Amino R, Sand C van de, Regen T, Retzlaff S, Rennenberg A, Krueger A, Pollok J-M,
658 Menard R, Heussler VT. 2006. Manipulation of Host Hepatocytes by the Malaria Parasite
659 for Delivery into Liver Sinusoids. *Science* **313**:1287–1290. doi:10.1126/science.1129720
660 Thomas R, Apps R, Qi Y, Gao X, Male V, O'hUigin C, O'Connor G, Ge D, Fellay J, Martin JN,
661 Margolick J, Goedert JJ, Buchbinder S, Kirk GD, Martin MP, Telenti A, Deeks SG,
662 Walker BD, Goldstein D, McVicar DW, Moffett A, Carrington M. 2009. HLA-C cell

663 surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C.
664 *Nat Genet* **41**:1290–1294. doi:10.1038/ng.486
665 Tran TM, Li S, Doumbo S, Doumtabe D, Huang C-Y, Dia S, Bathily A, Sangala J, Kone Y,
666 Traore A, Niangaly M, Dara C, Kayentao K, Ongoiba A, Doumbo OK, Traore B,
667 Crompton PD. 2013. An intensive longitudinal cohort study of Malian children and adults
668 reveals no evidence of acquired immunity to Plasmodium falciparum infection. *Clin*
669 *Infect Dis* **57**:40–47. doi:10.1093/cid/cit174
670 Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. 1998. Direct Binding and
671 Functional Transfer of NK Cell Inhibitory Receptors Reveal Novel Patterns of HLA-C
672 Allotype Recognition. *The Journal of Immunology* **161**:571–577.
673 World Health Organization. 2018. World Malaria Report 2017. Geneva, Switzerland: World
674 Health Organization.
675 Zaidi I, Diallo H, Conteh S, Robbins Y, Kolasny J, Orr-Gonzalez S, Carter D, Butler B, Lambert
676 L, Brickley E, Morrison R, Sissoko M, Healy SA, Sim BKL, Doumbo OK, Hoffman SL,
677 Duffy PE. 2017. γδ T Cells Are Required for the Induction of Sterile Immunity during
678 Irradiated Sporozoite Vaccinations. *The Journal of Immunology* ji1700314.
679 doi:10.4049/jimmunol.1700314
680